View source for 9jz2


==Crystal structure of the PIN1 and fragment 7 complex.==
<StructureSection load='9jz2' size='340' side='right'caption='[[9jz2]], [[Resolution|resolution]] 1.55&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[9jz2]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9JZ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9JZ2 FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.55&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1ED3:~{N}-(5-azanyl-2-methyl-phenyl)ethanamide'>A1ED3</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=PE8:3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL'>PE8</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9jz2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9jz2 OCA], [https://pdbe.org/9jz2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9jz2 RCSB], [https://www.ebi.ac.uk/pdbsum/9jz2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9jz2 ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/PIN1_HUMAN PIN1_HUMAN] Essential PPIase that regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Displays a preference for an acidic residue N-terminal to the isomerized proline bond. Catalyzes pSer/Thr-Pro cis/trans isomerizations. Down-regulates kinase activity of BTK. Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation.<ref>PMID:15664191</ref> <ref>PMID:16644721</ref> <ref>PMID:21497122</ref> 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Pin1 is a phosphorylation-dependent peptidyl-prolyl isomerase that specifically recognizes and catalyzes the cis-trans isomerization of pSer/Thr-Pro motifs. It plays a pivotal role in cell cycle regulation, signal transduction, and tumorigenesis. Due to its overexpression in many cancer types, Pin1 has emerged as a promising target for the development of anticancer drugs. However, the relatively shallow and flat surface of Pin1 presents significant challenges for traditional small-molecule inhibitor design. To overcome these limitations, we employed an X-ray crystallography-based fragment screening strategy and identified approximately 50 Pin1-fragment complex structures from a curated fragment library. Systematic structural analysis revealed several druggable binding hotspots, including the well-characterized catalytic center (Site 1) and a neighboring region near the catalytic residue Cys113 (Site 2). Both sites supported stable binding with diverse fragment scaffolds. Notably, several fragments displayed cooperative binding across multiple sites, highlighting their potential as scaffolds for multifunctional inhibitor design. Additionally, a subset of fragments showed reactivity toward Cys113, and their covalent binding modes were confirmed through crystallographic and mass spectrometric analyses. Enzymatic inhibition assays further demonstrated that several fragments effectively suppressed Pin1 activity in solution, validating their potential as lead compounds. In summary, this study systematically mapped functional binding pockets on Pin1 through a structure-driven fragment screening approach, expanded its druggable landscape, and identified key structural features and fragment chemotypes to guide the development of selective, well-defined Pin1 inhibitors.

Uncovering druggable hotspots on Pin1 via X-ray crystallographic fragment screening.,Xiao Q, Tang J, Shu H, Wu T, Zhang H, Wang W, Wang L, Qin W Eur J Med Chem. 2025 Aug 7;299:118048. doi: 10.1016/j.ejmech.2025.118048. PMID:40803165<ref>PMID:40803165</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 9jz2" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Qin WM]]
[[Category: Shu HL]]
[[Category: Wu TT]]
[[Category: Xiao QJ]]